Description
Duvelisib of Medication:
Copiktra (Duvelisib) is a kinase inhibitor used for the treatment of adult patients with: relapsed/refractory CLL or SLL after at least 2 earlier therapies. relapsed/refractory FL following at least 2 earlier systemic therapies.
Dosage: The recommended dosage is duvelisib 25 mg administered as oral capsules twice in a day with/without food. A cycle consists of 28 days. The capsules of duvelisib should be swallowed whole. Patients are advised to not open, break, or chew the capsules. Patients are advised that if a dose is missed by fewer than six hours, to administer the missed dose promptly and administer the next dose as usual. And if a duvelisib dose is missed by over six hours, patients are advised to wait and administer the next dose at about the usual time.
Side Effects: The most commonly reported duvelisib side effects may include:
- Diarrhea or Colitis
- Neutropenia
- Rash
- Fatigue
- Pyrexia
- Cough
- Nausea
- Anemia
- Upper respiratory infection
- Pneumonia
- Musculoskeletal pain
Warnings and Precautions:
Patients taking treatment with copiktra 25 mg are advised to report any new or worsening diarrhea. Patients with duvelisib therapy are advised of the need for periodic monitoring of blood counts. Patients should be monitored for the hepatic function during therapy with copiktra capsules. Females should inform their doctor if they are pregnant or become pregnant. Use of duvelisib 15 mg during pregnancy may be hazardous to the fetus.
